SHAOJIE HAN: Open Payments
NPI 1073811832 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,451 in 173 payments from 16 companies in 2025. Trend: 2023 $2,676 · 2024 $2,685 · 2025 $3,451
Food & beverage: $3,449Education: $2
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $552 |
| Neurocrine BioSciences, Inc. | 14 | $387 |
| Otsuka America Pharmaceutical, Inc. | 22 | $379 |
| Alkermes, Inc. | 15 | $320 |
| Corium, LLC | 20 | $302 |
| Lundbeck LLC | 12 | $278 |
| ABBVIE INC. | 14 | $217 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $211 |
| Teva Pharmaceuticals USA, Inc. | 13 | $185 |
| E.R. Squibb & Sons, L.L.C. | 7 | $178 |
Products named: CAPLYTA, REXULTI, INGREZZA, ARISTADA, Azstarys, VRAYLAR, TRINTELLIX, COBENFY.
Industry payments across TX — which companies pay providers there.
